Albania
Bosnia-Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Germany
Hungary
Italy
Kosovo
Latvia
Lithuania
Luxembourg
Macedonia
Montenegro
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Switzerland
Sweden
Turkey
United Kingdom
UAE
Hong Kong
Kuwait
Lebanon
South Africa
English 
Български 
Français 
Deutsch 
Ελληνικά 
Magyar 
Italiano 
Cрпски 
Español
Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 201 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 19 |
| 202 | Apheresis | Allogeneic | B-Cell Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 203 | Apheresis | Allogeneic | B-Cell Progenitor Acute Lymphoblastic Leukemia High Risk | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 204 | Apheresis | Allogeneic | Calr Positive Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 205 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 206 | Apheresis | Allogeneic | Chronic Myelogenous Leukaemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 207 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 208 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 35 |
| 209 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 42 |
| 210 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 49 |
| 211 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 72 |
| 212 | Apheresis | Allogeneic | Chronic Neutrophilic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 213 | Apheresis | Allogeneic | Fanconi Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 20 |
| 214 | Apheresis | Allogeneic | Follicular Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 215 | Apheresis | Allogeneic | High Risk Acute Myeloid Leukaemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 216 | Apheresis | Allogeneic | High Risk Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 217 | Apheresis | Allogeneic | High-Risk Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 218 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 27 |
| 219 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 27 |
| 220 | Apheresis | Allogeneic | Hodgkin Disease | Hematology | 2024 | Standard Therapy | Poland | 28 |
| 221 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 23 |
| 222 | Apheresis | Allogeneic | Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 223 | Apheresis | Allogeneic | Infant Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 224 | Apheresis | Allogeneic | Kutanes T-Zell-Lymphom, Mycosis Fungoides | Hematology | 2024 | Standard Therapy | Poland | 72 |
| 225 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 51 |
| 226 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 64 |
| 227 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 228 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 52 |
| 229 | Apheresis | Autologous | Morbus Hodgkin | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 230 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Poland | 43 |
| 231 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 52 |
| 232 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 54 |
| 233 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 234 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 235 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 236 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 237 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 238 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 239 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 240 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 64 |
| 241 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 242 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 243 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 244 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 245 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 67 |
| 246 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 68 |
| 247 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 248 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 70 |
| 249 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 71 |
| 250 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 72 |
| 251 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 66 |
| 252 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 253 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 254 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 255 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 256 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 257 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 70 |
| 258 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 74 |
| 259 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 260 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 261 | Apheresis | Allogeneic | Myelodysplastic | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 262 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 20 |
| 263 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 22 |
| 264 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 265 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 266 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 267 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 268 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 269 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 270 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 271 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 272 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 273 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 274 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 275 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 71 |
| 276 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 73 |
| 277 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 278 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 53 |
| 279 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 280 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 281 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 282 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 49 |
| 283 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 284 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 285 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 286 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 287 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 288 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 289 | Apheresis | Allogeneic | Myelodysplastic Syndrome + Myeloma | Hematology | 2024 | Standard Therapy | Germany | 67 |
| 290 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 40 |
| 291 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 292 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 293 | Apheresis | Allogeneic | Myelofibrosis Post. Polycythemia Vera | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 294 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 295 | Apheresis | Allogeneic | Myeloma | Hematology | 2024 | Standard Therapy | Germany | 65 |
| 296 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2024 | Standard Therapy | Poland | 74 |
| 297 | Apheresis | Allogeneic | Myeloproliferative Neoplasms/Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 298 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 23 |
| 299 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Germany | 50 |
| 300 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 50 |